Certara (CERT) Stock Forecast & Price Target

Certara is a fast-growing company in the drug discovery and development industry, with a strong focus on biosimulation software and technology. Their recent 2Q26 production results showed an impressive 35% YoY increase in production, driven by success in their CIL and heap-leach circuits. While there may be short-term headwinds from the divestiture of their R&MW business, their long-term outlook is positive, with a focus on AI-driven initiatives and a partnership with NVDA to improve their biosimulation capabilities. Despite some modest negatives, we believe Certara has strong fundamentals and potential for growth, making it an attractive investment opportunity.

Certara is currently positioned for near-term choppiness as the company absorbs reset actions upfront, and while the margin guide appears achievable, any upside to guidance requires a stronger services recovery. This, combined with the fact that software bookings only make up 20% of the company's revenue, and the mix has been shifting back toward services, raises concerns about the sustainability and predictability of the company's growth and margins in the long term. The recent divestiture of R&MW will likely help align Certara's business and improve operational efficiencies, but there are still risks to achieving the target price due to a heavy reliance on services and potential margin headwinds from this mix shift.